210 related articles for article (PubMed ID: 16795032)
1. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate.
Fernandez Gacio A; Fernandez-Marcos C; Swamy N; Dunn D; Ray R
J Cell Biochem; 2006 Oct; 99(3):665-70. PubMed ID: 16795032
[TBL] [Abstract][Full Text] [Related]
2. Nuclear estrogen receptor targeted photodynamic therapy: selective uptake and killing of MCF-7 breast cancer cells by a C17alpha-alkynylestradiol-porphyrin conjugate.
Swamy N; Purohit A; Fernandez-Gacio A; Jones GB; Ray R
J Cell Biochem; 2006 Oct; 99(3):966-77. PubMed ID: 16741968
[TBL] [Abstract][Full Text] [Related]
3. Internalization of a C17α-alkynylestradiol-porphyrin conjugate into estrogen receptor positive MCF-7 breast cancer cells.
Sadler S; Persons KS; Jones GB; Ray R
Bioorg Med Chem Lett; 2011 Aug; 21(15):4638-41. PubMed ID: 21704522
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
7. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
8. Studies on tamoxifen encapsulated in lipid vesicles: effect on the growth of human breast cancer MCF-7 cells.
Bhatia A; Bhushan S; Singh B; Katare OP
J Liposome Res; 2009; 19(3):169-72. PubMed ID: 18991067
[TBL] [Abstract][Full Text] [Related]
9. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
[TBL] [Abstract][Full Text] [Related]
10. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
[TBL] [Abstract][Full Text] [Related]
13. Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells.
Lee JH; Lu HF; Wang DY; Chen DR; Su CC; Chen YS; Yang JH; Chung JG
Res Commun Mol Pathol Pharmacol; 2004; 115-116():217-33. PubMed ID: 17564319
[TBL] [Abstract][Full Text] [Related]
14. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
15. Effect of vitamin E on tamoxifen-treated breast cancer cells.
Peralta EA; Viegas ML; Louis S; Engle DL; Dunnington GL
Surgery; 2006 Oct; 140(4):607-14; discussion 614-5. PubMed ID: 17011908
[TBL] [Abstract][Full Text] [Related]
16. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells.
Lagadec C; Adriaenssens E; Toillon RA; Chopin V; Romon R; Van Coppenolle F; Hondermarck H; Le Bourhis X
Oncogene; 2008 Feb; 27(10):1472-7. PubMed ID: 17767197
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
[TBL] [Abstract][Full Text] [Related]
19. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G
Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
